Monday, September 14, 2026

North Korea’s New Destroyer Gets Stuck on the Ramp

North Korea's destroyer launch mishap angered Kim Jong Un, leading to investigations and potential delays in military deployment plans.

2026 Update: Wonsan Kalma Coastal Resort Nears Completion—Is North Korea Ready for Tourists?

Recent satellite images show North Korea's Wonsan-Kalma Tourist Zone nearing completion, signaling a potential resumption of foreign tourism.

North Korea’s 2026 Party Congress: Why Kim Downplayed Russia and China—Then Let a Parade Wave the Russian Flag

North Korea's 9th Party Congress downplays ties with Russia and China, emphasizing self-reliance and Kim Jong Un's leadership amid rising international standing.

Tag: drugs

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Dongkoo Bio&Pharma Invests 1 Billion KRW in GenomAndCompany: What This Means for ADC Drug Development

Dongkoo Bio&Pharma invests 1 billion KRW in Genome & Company to enhance antibody and ADC drug development strategies.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

High on Gummies: The New Disturbing Marijuana Trend

The police arrested several people after ingesting gummies with cannabis components and reporting symptoms of dizziness to 119, the Korean Emergency Service. On the 12th,...

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.